CLCS - Cell Source, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
Operating expenses
Research development
1,756
1,323
998.554
2,630
Selling general and administrative
1,933
2,695
2,639
1,175
Total operating expenses
3,689
4,019
3,638
3,805
Operating income or loss
-3,689
-4,019
-3,638
-3,805
Interest expense
882.686
1,361
937.406
307.947
Total other income/expenses net
-
-93.16
15.277
-362.347
Income before tax
-4,665
-5,472
-4,560
-4,475
Income from continuing operations
-4,665
-5,472
-4,560
-4,475
Net income
-4,665
-5,472
-4,560
-4,475
Net income available to common shareholders
-5,813
-6,446
-5,438
-5,217
Basic EPS
-
-0.19
-0.19
-0.18
Diluted EPS
-
-0.19
-0.19
-0.18
Basic average shares
-
33,117
29,099
28,329
Diluted average shares
-
33,117
29,099
28,329
EBITDA
-
-4,112
-3,623
-4,168